Vericel is like the Vertex Pharmaceuticals of cellular therapies for severe burns and knee cartilage repair.

Vericel is like a specialized Regeneron, but focused on advanced cellular treatments for severe burns and damaged joints.

• MACI: An autologous cellularized scaffold product used for the repair of symptomatic, full-thickness cartilage defects of the knee.
• Epicel: A permanent skin replacement humanitarian use device for treating deep-dermal or full-thickness burns in adult and pediatric patients.
• NexoBrid: A biological orphan product currently in the registration stage, intended for eschar removal in adults with deep partial-thickness and/or full-thickness thermal burns.

Vericel Corporation sells its specialized cellular therapies directly to healthcare institutions, rather than to individual patients. Based on the company's business model for products like MACI, Epicel, and NexoBrid, its sales are distributed across a broad network of medical facilities in the United States. Vericel does not typically disclose specific major customer companies by name, as its products are sold to a large number of providers, and no single customer is reported to have a material adverse effect on its business.

Therefore, the primary categories of customers that Vericel serves are:

• Hospitals: Healthcare facilities that administer treatments for severe burns (Epicel, NexoBrid) and perform orthopedic procedures (MACI).
• Burn Centers: Specialized units within hospitals focused on treating patients with deep-dermal or full-thickness burns.
• Orthopedic Clinics: Medical practices or departments specializing in the diagnosis and treatment of musculoskeletal conditions, where MACI for cartilage repair would be utilized.

• B. Braun Medical Inc.
• Eurofins Scientific (EPA.PA)
• Grifols S.A. (GRF.MC, GRFS)
• Lonza Group Ltd. (LONN.SW)

Dominick Colangelo, President & CEO

Nick Colangelo joined Vericel in 2013 with more than twenty years of executive management and corporate development experience in the biopharmaceutical industry. He spent nearly a decade with Eli Lilly and Company, where he held positions as Director of Strategy and Business Development for Lilly's Diabetes Product Group and served as a founding Managing Director of Lilly Ventures. He is credited with spearheading the acquisition of MACI and Epicel, which transformed the company into the commercial-stage Vericel.

Joe Mara, Chief Financial Officer

Joe Mara joined Vericel in 2021, bringing over 20 years of financial, strategic, and operational experience, including more than 14 years in the biotech industry. Prior to Vericel, he served as Vice President, Finance and Head of Investor Relations at Biogen Inc., where he held various finance leadership roles, including Vice President, Global Financial Planning and Analysis and Strategic Corporate Finance, and Vice President, U.S. Finance and Operations. He also held finance and strategy roles at Thomson Reuters Corporation and Fidelity Investments.

Mike Halpin, Chief Operating Officer

Mike Halpin oversees Vericel's day-to-day operations and is responsible for ensuring the complex manufacturing and distribution of products. He previously held roles at Sanofi and Genzyme Corporation, including vice president, North American region regulatory head for Sanofi Genzyme's rare disease, immuno-inflammatory, multiple sclerosis, and other business unit products. He also served as vice president, regulatory affairs for Genzyme's biosurgery division, with regulatory oversight of products such as Carticel®, Epicel®, and MACI®.

Jonathan Hopper, Chief Medical Officer

Dr. Jonathan Hopper joined Vericel in August 2018. He has over 15 years of experience in the clinical research industry. His previous roles include Senior Medical Director, Orthopedic Clinical Development for Ferring Pharmaceuticals, and Vice President, Global Medical Director for Stryker Corporation. Dr. Hopper also possesses significant medical device regulatory experience, having served as a Senior Medical Officer for the UK Medicines and Healthcare products Regulatory Agency.

Patrick Fowler, Senior Vice President, Corporate Development and Strategy

Patrick Fowler joined Vericel in 2021 with over 15 years of business development, strategy, and operations experience in the biotechnology and medical technology industries. Before Vericel, he was Head, North America Strategy, Operations & New Product Development for Sanofi (formerly Genzyme Corporation), where he guided business development, lifecycle management, and go-to-market strategy efforts for General Medicines and Established Products. He also held several corporate development roles at Genzyme.

1. Dependence on MACI and Potential for Capped Demand: Vericel's future growth largely hinges on the successful scaling and adoption of MACI, its autologous cellularized scaffold product for knee cartilage repair. The demand for Vericel's products, including Epicel and NexoBrid, may be limited due to their specialized and "needs-based" nature in niche markets, potentially capping future upside if new patient populations or expanded indications are not successfully addressed.
2. Operational and Manufacturing Challenges: The company is exposed to risks related to its manufacturing operations, including potential disruptions in the supply chain, changes in customer demand, and significant fluctuations in quarterly and annual results. Furthermore, the transition to and qualification of new manufacturing facilities, such as the Burlington plant for MACI, introduces execution risks. Delays in qualification or higher fixed costs and operational complexities could outpace revenue growth if utilization lags, impacting the company's ability to meet demand.
3. Regulatory Hurdles: As a biopharmaceutical company, Vericel's products are subject to stringent FDA regulations. Obtaining and maintaining regulatory approvals for existing products and for new indications, such as MACI for ankle cartilage defects, presents significant risks. Any delays or failures in securing these crucial approvals could adversely affect Vericel's product development, commercialization efforts, and overall growth trajectory.

Vericel Corporation operates in the United States with several key products addressing specific medical markets.

For their sports medicine product, MACI (autologous cultured chondrocytes on porcine collagen membrane), the addressable market for knee cartilage repair in the U.S. is estimated to be over $3 billion annually. Some estimates for MACI's total addressable market in the U.S., considering procedure volume and cost, range from $7.6 billion to $13.5 billion annually. Additionally, there is a potential for an extra $1 billion U.S. addressable market if MACI's indication expands to include ankle cartilage defects.

In the severe burn care market, Vericel's products include Epicel and NexoBrid. The U.S. total addressable market for their burn care franchise, which encompasses both Epicel and NexoBrid, is estimated at $600 million, with $300 million attributed to Epicel and $300 million to NexoBrid. Epicel is a permanent skin replacement for patients with deep dermal or full-thickness burns covering 30% or more of their total body surface area. NexoBrid, indicated for eschar removal in adults and pediatric patients with deep partial-thickness and/or full-thickness thermal burns, has an addressable market of $300 million in the U.S.

Vericel (NASDAQ: VCEL) is expected to drive future revenue growth over the next 2-3 years through several key initiatives:

1. Expanded Adoption and Utilization of MACI: Vericel anticipates continued revenue growth from its MACI product for knee cartilage repair, particularly through the increasing adoption of the arthroscopic MACI Arthro technique, which received FDA approval and launched in 2024. This method allows surgeons to deliver the MACI implant through smaller incisions, expanding its market. The company is also focusing on targeting more surgeons and increasing the number of MACI biopsies and conversion rates, supported by a recently expanded MACI sales force.

2. Expansion of MACI into New Indications: A significant long-term growth driver for MACI is its potential expansion into new anatomical indications beyond the knee. Vericel is advancing a pivotal ankle trial (MASCOT) and plans to initiate a Phase III clinical study for MACI Ankle in the second half of 2025 or fourth quarter of 2026, aiming to tap into a substantial addressable market for ankle cartilage repair.

3. Continued Growth and Market Penetration of the Burn Care Franchise: The company's burn care portfolio, consisting of Epicel and NexoBrid, is expected to be a strong revenue driver. NexoBrid, which received FDA approval for a pediatric indication and is early in its launch phase, is gaining traction with increased hospital orders and Pharmacy and Therapeutics (P&T) committee approvals. Vericel aims to leverage its unique burn portfolio to expand the number of burn centers and surgeons utilizing both Epicel and NexoBrid. Additionally, there is potential for a BARDA (Biomedical Advanced Research and Development Authority) agreement for NexoBrid stockpiling and development, which could further bolster this segment.

4. International Expansion for MACI: Vericel is pursuing international market entry for MACI. This includes plans for a UK launch via the MHRA's (Medicines and Healthcare products Regulatory Agency) recognition pathway, with a regulatory submission anticipated in mid-2026 for a potential 2027 launch. This geographic expansion represents a new market opportunity for the company's leading sports medicine product.

5. Increased Manufacturing Capacity: The FDA approval of Vericel's new Burlington, Massachusetts, facility to commence commercial manufacturing of MACI in the second quarter of 2026 is crucial for supporting future revenue growth. This facility is designed to become the primary global manufacturing site for MACI and Epicel, significantly enhancing production capabilities to meet rising demand and enable the company's expansion strategies.

Share Issuance

• Total shares outstanding have increased by 3 million over the last three years (ending Q4 2025).

Capital Expenditures

• Vericel has engaged in ongoing capital spending on property, plant, and equipment, and other investments, contributing to a steady cash outflow and negative cash flow from investing in several quarters.
• A significant portion of capital expenditures has been directed towards the new Burlington facility for MACI commercial manufacturing.
• Increased operating expenses in 2025 were partly attributable to additional costs associated with the new Burlington facility, including depreciation and manufacturing start-up activities for MACI.